GSK’s Arexvy Is First RSV Vaccine Approved By FDA, But A Second Is Poised To Follow

Arexvy will launch in the US in time for the fall 2023 RSV season for adults 60 and older, GSK said. Pfizer’s Abrysvo is also pending at the FDA.

GSK got its RSV vaccine across the FDA finish line first • Source: Shutterstock

GSK plc’s Arexvy is the first vaccine approved for respiratory syncytial virus (RSV) by the US Food and Drug Administration. The approval is an accomplishment, but the vaccine is likely to face a challenge in the commercial market from the coinciding launch of a timely rival.

Pfizer Inc. also expects the FDA to rule on its RSV vaccine, Abrysvo, in the near-term, and both vaccines...